Carregant...
AI-01 ARE WE USING TOO MUCH BEVACIZUMAB IN OUR GBM PATIENTS?
INTRODUCTION: Compared to traditional chemotherapies, where dose limiting toxicities represent the maximum possible dose, monoclonal antibody therapies are used at doses well below MTD. However, there has been little effort to ascertain whether there is a submaximal dose at which the efficacy/compli...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4217847/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou238.1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|